氯氮平监测要求：是时候更新了吗？

Clozapine monitoring requirements: is it time for an update?

作者信息

Fernandez-Egea Emilio, McCutcheon Robert A

机构信息

Cambridgeshire and Peterborough NHS Foundation Trust and Department of Psychiatry, University of Cambridge, Cambridge, UK.

Department of Psychiatry, University of Oxford, Oxford, Oxford Health NHS Foundation Trust, Oxford and Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

出版信息

Br J Psychiatry. 2025 Jan;226(1):1-3. doi: 10.1192/bjp.2024.150.

DOI:10.1192/bjp.2024.150

PMID:39359180

Abstract

Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. The editorial supports calls for international consensus to carefully weigh the pros and cons of relaxing monitoring guidelines while ensuring comprehensive care for patients.

摘要

奥洛耶德及其同事主张更新氯氮平的血液学监测要求，认为现行方案高估了氯氮平诱发粒细胞缺乏症的风险。他们的研究表明，严格的监测可能会不必要地限制氯氮平的使用，而氯氮平是治疗难治性精神分裂症的关键药物。这篇社论支持呼吁达成国际共识，在确保为患者提供全面护理的同时，仔细权衡放宽监测指南的利弊。